Drug testing changes coming January 1, 2018
By: Betty Weiland
Publication: Alcohol & Drugs: DOT Compliance Manual
Date Posted: 12/21/2017
Effective January 1, 2018, several drug testing procedures in 49 CFR Part 40 are changing. One change concerns the drugs that are tested for. The previous category of “opiate metabolites” was renamed to “opioids” to more accurately describe the group, due to the addition of four new opioids to the DOT drug panel. The four opioids being added are hydrocodone, hydromorphone, oxymorphone, and oxycodone.
Another change deals with prescription drugs. When a prohibited drug is found in a DOT urine specimen, the medical review officer (MRO) will verify whether it was legally prescribed. If it was, the test is reported to the employer as a negative. However, effective January 1, 2018, the MRO is authorized to question the use of the medication, despite the negative result, if he or she believes there is a medical qualification issue or safety risk.
The MRO will discuss the concerns with the driver. The driver will be told that he or she has five days from the date of the reported negative result to contact the prescribing physician about getting another medication that mitigates the concerns.
If the five days expire or no alternatives are made available, the MRO must report the possible medical disqualification (see Section 40.327) to all entities that are applicable to the situation, including the driver’s medical examiner and the employer.
Get the compliance manual that will help you understand the Alcohol and Drug Testing requirements and explore the related issues.
This easy-to-use manual can help you understand and comply with DOT's Alcohol and Drug Testing requirements, including 49 CFR Parts 382 and 40. Word-for-word requirements and "how to" explanations help develop written policies, manage training, comply with recordkeeping guidelines and more. More Info